TGFB1 and plasma cell myeloma: In DLBCL, the pathway was previously reported to be recurrently inactivated (54), but in multiple myeloma and myeloproliferative disorders, TGF-β exerted pro-tumor activity by inhibiting host tumor immune surveillance.